Enveric Biosciences, Inc.

NasdaqCM ENVB

Enveric Biosciences, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2024

Enveric Biosciences, Inc. EPS (Diluted) is NA for the Trailing 12 Months (TTM) ending September 30, 2024. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.
  • Enveric Biosciences, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -13.30, a 86.21% change year over year.
  • Enveric Biosciences, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -96.44.
Key data
Date EPS (Diluted) Shares (Diluted, Weighted) Shares (Basic, Weighted) Revenue
Market news
SV Wall Street
NasdaqCM: ENVB

Enveric Biosciences, Inc.

CEO Dr. Joseph Edward Tucker Ph.D.
IPO Date May 4, 2015
Location United States
Headquarters 4851 Tamiami Trail North
Employees 7
Sector Healthcare
Industries
Pharmaceuticals Biotechnology Clinical Trials Cosmetics Drugstores & Retail Pharmacies Mental Health Personal Care Tobacco
Description

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Similar companies

ZURA

Zura Bio Limited

USD 1.78

4.09%

StockViz Staff

February 6, 2025

Any question? Send us an email